Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
5.92
+0.02 (0.34%)
At close: Jul 7, 2026, 4:00 PM EDT
5.81
-0.11 (-1.85%)
After-hours: Jul 7, 2026, 5:59 PM EDT
MRVI Revenue
Maravai LifeSciences Holdings had revenue of $65.84M in the quarter ending March 31, 2026, with 40.53% growth. This brings the company's revenue in the last twelve months to $204.73M, down -15.35% year-over-year. In the year 2025, Maravai LifeSciences Holdings had annual revenue of $185.74M, down -28.34%.
Revenue (ttm)
$204.73M
Revenue Growth
-15.35%
P/S Ratio
7.45
Revenue / Employee
$492,139
Employees
416
Market Cap
1.53B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 185.74M | -73.44M | -28.34% |
| Dec 31, 2024 | 259.19M | -29.76M | -10.30% |
| Dec 31, 2023 | 288.95M | -594.06M | -67.28% |
| Dec 31, 2022 | 883.00M | 83.76M | 10.48% |
| Dec 31, 2021 | 799.24M | 515.14M | 181.33% |
| Dec 31, 2020 | 284.10M | 140.96M | 98.48% |
| Dec 31, 2019 | 143.14M | 19.31M | 15.59% |
| Dec 31, 2018 | 123.83M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.71B |
| Novavax | 596.34M |
| Innoviva | 420.69M |
| Immunocore Holdings | 412.81M |
| Septerna | 72.26M |
| Vir Biotechnology | 65.50M |
MRVI News
- 21 days ago - Maravai Lifesciences announces opening of GMP enzyme manufacturing facility - TheFly
- 21 days ago - TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale - Business Wire
- 4 weeks ago - Maravai LifeSciences Holdings Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Maravai Lifesciences announces refinancing of credit agreement - TheFly
- 4 weeks ago - Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032 - Business Wire
- 7 weeks ago - Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - Maravai Lifesciences price target raised to $6 from $4.50 at Deutsche Bank - TheFly
- 2 months ago - Maravai LifeSciences Holdings Slides: Investor presentation - Filings